```text

Wiki Article

Abciximab (C7E3, 143653-53-6): A Research Reagent Overview

Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable research compound extensively used in platelet studies . This Fab fragment selectively targets the glycoprotein IIb/IIIa receptor on platelets , inhibiting platelet aggregation . Consequently , it's commonly applied as a method to explore the mechanisms underlying clotting and to determine the effectiveness of anticoagulant therapies. Supply is typically controlled to institutional settings.

```

Abciximab Drug Research: Utilizing The C7E3 Fragment and The 143653-53-6 Substance in Scientific Assessments

Ongoing investigation into abciximab, a GPIIb/IIIa, frequently employs the monoclonal antibody C7E3 and the molecule identified as 143653-53-6. These reagents are essential for analyzing abciximab's mechanism of action, determining its effectiveness in experimental conditions, and elucidating potential indicators of treatment response. Continued exploration leveraging these precise reagents is predicted to yield valuable data for optimizing clinical applications involving cardiovascular illness.

```text

C7E3 Abciximab (143653-53-6) - Applications in Scientific Research

C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing check here investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }

```

```text

Investigating Research Possibilities with Abciximab 143653-53-6 via C7E3

Recent research demonstrate that this antiplatelet agent (identified as 143653-53-6) holds significant investigative potential, particularly when associated with a C7E3 construct. Preliminary observations indicated that this association may improve clinical responses in multiple heart-related conditions. Further exploration is focused on defining the specific mechanism of effect between Abciximab and C7E3, involving study of blood clot aggregation and vascular preservation.

  • Current study efforts intend to maximize delivery strategies.
  • Laboratory approaches are being employed to further validate the propositions.
  • Clinical trials will be essential to completely determine clinical benefit.

```

Abciximab (C7E3) for Research: Purity and Specifications (143653-53-6)

Researchers seeking abciximab for experimental research should rigorously evaluate integrity and precise specifications . The compound is typically provided as a solid powder and detailed analytical data including assessment by mass spectrometry , potency assays, and endotoxin testing are available. Verify the source’s documentation clearly states required limits for impurities and fulfills relevant quality assurance criteria .

Research-Grade ReoPro Details & Supply

Acquiring laboratory-grade Abciximab, specifically referencing the compound C7E3 and identified by the catalog number 143653-53-6, requires detailed consideration of its origin . This glycoprotein is widely utilized in cell-based experiments, particularly those focused on platelet aggregation and thrombosis . Current sources offer this substance in varying volumes, typically ranging from milligram to substantial commercial amounts . Kindly suggest reviewing the report of quality to verify integrity and suitability for your specific use . Furthermore , ensure the expiration date before purchasing to maintain maximum efficacy .

  • Common Purity: >95%
  • Preservation Conditions: -20°C and suitable conditions
  • Application : Platelet Aggregation Suppression Studies

Report this wiki page